ALIM — Alimera Sciences Balance Sheet
0.000.00%
- $301.29m
- $360.44m
- $80.75m
- 37
- 33
- 89
- 51
Annual balance sheet for Alimera Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 9.43 | 11.2 | 16.5 | 5.27 | 12.1 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 19.3 | 17.2 | 19.1 | 19.6 | 34.5 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 32.7 | 34.9 | 42.2 | 29.4 | 52.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.05 | 2.36 | 4.49 | 3.92 | 3.59 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 50.3 | 50.9 | 58.5 | 42.6 | 154 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 12 | 12.3 | 12.6 | 39.7 | 21.9 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 54.8 | 58.8 | 61.1 | 63.4 | 107 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -4.45 | -7.98 | -2.6 | -20.8 | 46.2 |
| Total Liabilities & Shareholders' Equity | 50.3 | 50.9 | 58.5 | 42.6 | 154 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |